CEO of Toboggan Labs’ Florencia Herra Vega discusses AI compliance and innovation, applying AI to the whole team instead of individually, and useful technology for quick solutions.

Country Manager of Merz Therapeutics’ Mike Stone discusses commercial launches, the speed of mid-sized pharma, and rebranding DEI.

Leverage’s Ian Howard discusses his time working in the public sector, treating illness versus promoting wellness, and the rise of cosmetic dermatology.

National Director of Account Management of Sales of IQVIA’s Chris Hankey discusses biobanking, digital transformation, and better health outcomes for patients.

Director of Business Development of Bayshore Specialty Rx’s Shaminder Singh discusses patient support and care delivery, building adaptability and resilience into patient support programs, and the future of healthcare funding in Canada

Head of Canadian Commercial Operations and Strategic Advisor of EMD Serono’s Khalid Sabihuddin discusses translating complex analytics into actionable guidance, international healthcare perspectives, and the healthcare policy climate.

Co-Chairman of BridgeBright Advisors’ Mike Cloutier discusses leadership at scale, leadership in the current political climate, and the hardware for being a successful leader.

Pangaea Consultants’ Managing Director Jeff Martens discusses going from an operating role to consulting, lack of access in today’s political climate, and doing less with more.

Seaford President Tamara Seales discusses navigating Canadian pharma regulations, team-building, and weaving DEI into the fabric of the company.

Mike Exton, CEO and Board Director of Lexicon Pharmaceuticals, talks about safeguards and limits for AI, smaller pharma veresus big pharma, and brand strategies based on data over belief.